Empiric dose reductions for variant DPYD alleles isn't necessarily new, but the outcomes of patients treated with those dose reductions isn't well described. Dutch researchers provide some much needed evidence.
Link: https://pubmed.ncbi.nlm.nih.gov/?term=37639651
Is there a role for ICIs in dMMR/MSI-h pancreatic cancer? This retrospective says, uh maybe probably.
Link: https://pubmed.ncbi.nlm.nih.gov/?term=37625102
